Institut für Pathologie
Trogerstrasse 18
D-81675 München
The lab page of Karl-Friedrich Becker
- Clinical Proteomics -
Protein extraction from formalin fixed tissues for quantitative analysis
using protein microarrays
Meet me at:
4-5 September 2007, Amsterdam, Netherlands
See our latest publications:
-
Becker KF, Schott C, Hipp S, Metzger V, Porschewski P, Beck R, Nahrig J, Becker I, Hofler H. Quantitative protein analysis from formalin-fixed tissues: implications for
translational clinical research and nanoscale molecular diagnosis. J Pathol. 2007 Feb;211(3):370-8 -
Becker KF, Metzger V, Hipp S, Hofler H. Clinical proteomics: new trends for protein microarrays. Curr Med Chem. 2006;13(15):1831-7
For the development of novel proteomic techniques to identify new or more specific molecular markers, the realities in the clinic are rarely taken into account. For that reason translation of these methods into the clinic lacks far behind applications in basic sciences. Formalin fixed samples have been used since decades to distinguish diseased from normal tissues all over the world. No routine method has been available so far for quantitation of intact proteins from formalin fixed tissues. We succeeded in the isolation of intact, soluble and immunoreactive proteins from formalin fixed tissues routinely processed in our hospital.
Our technology is compatible with a variety of assay formats, such as:
Western blot
Reverse phase protein microarray
Antibody microarray
Direct clinical application
Proof by Western blot: No protein degradation, no background.
(Detection of beta-Actin (42 kDa) extracted from 9 formalin fixed colon cancers.)
Western blot and reverse phase protein microarray correlate excellently, as shown by serial dilutions.
(Ab against E-cadherin, 120 kDa).
© 2003-2006 Dr. Karl-Friedrich Becker,
Institut für Pathologie, TU München
Protein extraction from formalin fixed tissues for microarray analysis - it works!
Using protein microarrays, our technique can be used to quantify known molecular markers and to identify novel disease markers in high throughput and in an automatic fashion in clinical samples.
Academic and industrial researchers interested in our technology are invited to contact us for further information and possibilities of collaborations.